Estradiol enanthate
chemical compound
Estradiol enanthate (EEn or E2-EN), also spelled estradiol enantate and sold under the brand names Perlutal and Topasel among others, is an estrogen medication which is used in hormonal birth control for women. It is formulated in combination with dihydroxyprogesterone acetophenide (DHPA; algestone acetophenide), a progestin, and is used specifically as a combined injectable contraceptive. Estradiol enanthate is not available for medical use alone. The medication, in combination with DHPA, is given by injection into muscle once a month.
Side effects of estradiol enanthate include breast tenderness, breast enlargement, nausea, headache, and fluid retention. Estradiol enanthate is an estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It is an estrogen ester and a long-lasting prodrug of estradiol in the body. Because of this, it is considered to be a natural and bioidentical form of estrogen.
Estradiol enanthate was first described by 1954, and was first studied in combination with DHPA as a combined injectable contraceptive in 1964. The combination was introduced for clinical use by the mid-1970s.
The public source identifies “Estradiol enanthate” as chemical compound. This brief keeps that definition visible, then builds a research path around Estradiol, enanthate and chemical.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Estradiol enanthate”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated May 15, 2026. The linked authority identifier is Q5401763. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1954 and 1964.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Estradiol enanthate”, its source revision and the description used here.
- Expand the search: follow Estradiol enanthate primary sources, Estradiol enanthate archive and Estradiol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Estradiol enanthate”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Estradiol enanthate” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.